April 15, 2024

FREDERICK, Md.June 16, 2023 /PRNewswire/ -- Texcell is pleased to announce the opening of their newest testing facility in North America, representing a significant milestone in Texcell's commitment to advancing the viral safety of biotherapeutics and medical devices. Designed to support simultaneous viral clearance and biosafety studies, this 27,000 sq ft facility is built with a modular design that enhances the flexibility required in today's contract testing environment. Texcell – North America's dedicated teams are ready to support biosafety studies for monoclonal antibodies, gene therapies, and medical devices coming to the market.

The unveiling event was preceded by an exclusive luncheon attended by esteemed international and local dignitaries, exemplifying the company's dedication to bridging the gap between the regional community and global awareness. In attendance at the inauguration was Laurent Bili, Ambassador of France to the United StatesFrederick Mayor Michael O'Connor, Deputy Secretary of the Maryland Department of Commerce, Signe Pringle, Executive Director of Economic and Workforce Development for FrederickLara Fritts, President of Texcell's parent company, Soparbiotech International, Céline Saint Olive Baque, CEO of Soparbiotech International and President of Texcell SA, Dr. Éric B. Henriet, as well as other executive Texcell Group employees. 

April Schubert, Deputy CBO & Director of Sales and Marketing at Texcell Group and one of the original employees at the Frederick location, spoke with the dignitaries about Texcell's key role in ensuring the safety of biotherapeutics. In addition to the exclusive luncheon, Texcell hosted an open ribbon cutting ceremony that included current and former Texcell team members, as well as local clients and vendors to celebrate the inaugural opening, with certificates presented by Maryland's Department of Commerce and County Executive Fitzwater's office. Alysia Birkholz, Texcell – North America's Deputy CEO, led a toast that spoke to Texcell's ongoing mission to prioritize patient safety as embodied in the company's new slogan, "Protecting Tomorrow's Medicines, Today".

About Texcell

Texcell is a contract research organization that specializes in viral testing, viral clearance, bioassays, in vivo testing, and GMP cell banking, for R&D, GClP, GLP and GMP projects.

The Texcell group employs 140 people in France, in the United States, in Germany and in Asia (China and Japan) and counts customers worldwide. To sustain its continuous growth, Texcell will inaugurate in 2023 two new laboratories, in the United States and in China.

SOURCE - Texcell

CAMPBELL, Calif.--(BUSINESS WIRE)--Saama, a provider of AI- and ML-based solutions that accelerate clinical development and commercialization, announced today the launch of its unified platform of SaaS-based products to accompany its existing portfolio of customized solutions and services.

When using Saama’s advanced solutions, clinical trial sponsors and CROs reduce query identification and generation times by as much as 90% per query, realize up to 50% time savings for study data transformations, reduce time from data entry to analysis by more than 35%, and more.

The new Saama platform deploys its proven artificial intelligence (AI)- and machine learning (ML)-enhanced solutions to automate key clinical development processes and provide a holistic view of trial operations and patient progress in one location.

“Life science companies face significant headwinds in terms of the complexity and cost of conducting clinical research and bringing new treatments to market,” said Vivek Sharma, Chief Executive Officer, Saama. “Saama’s unified platform demonstrates to trial sponsors and CROs the power of automation to drive efficiencies as well as enable greater visibility into clinical data to deliver novel treatments to patients.”

Today’s clinical research and development environment is faced with many challenges, including the cost of developing novel treatments, pressure to bring a greater number of therapies to market faster, the increasing volume and velocity of patient data, and a shortage of talent to bring life-changing therapies to patients who need them.

By applying AI and advanced analytics to key clinical development processes, Saama’s platform eliminates manual, resource-intensive activities, allowing life science organizations to optimize productivity as well as gain deeper insights into patients’ behaviors and their real-time response to treatments.

AI models take years and millions of data points to train accurately. Saama has nearly a decade of AI research with 90+ models built for life sciences and trained on over 300 million data points. These models are embedded directly within the Saama platform, allowing for the fast and seamless deployment of new models within existing products as the platform continues to evolve and scale to meet the needs of customers.

“We have the ability to fundamentally change the way we run clinical trials – to be more efficient and to transform how we collect and analyze data,” said Lisa Moneymaker, Chief Technology Officer and Chief Product Officer, Saama. “By unifying our product suite into the Saama platform, we have the foundation to support clinical trials in a repeatable and scalable way. We will continue to build on this infrastructure to unleash new products that help to speed new treatments through the drug development process and into the hands of the patients that need them most.”

The Saama platform supports the full spectrum of clinical development with its portfolio of AI-enabled SaaS solutions comprised of:

  • Data Hub – the most robust solution available today that centralizes and standardizes clinical, operational, financial, and more data in a single location.
  • Operational Insights – provides a holistic view of trial operations, in real time, to all team members and seamlessly visualizes clinical, operational, and financial data, including EDC, CTMS, and eTMF data.
  • Patient Insights – centralizes and visualizes patient data in a single location – as well as applies AI to patient data in real time – allowing researchers to predict patient behavior, track progress, and even accelerate clinical signal discovery.
  • Source to Submission (S2S) – automates the complex SDTM transformation process with advanced AI/ML allowing sponsors to simplify and accelerate their regulatory submissions.
  • Smart Data Quality (SDQ) – automates data cleaning, review, and reconciliation processes for data managers, reducing query generation times by as much as 90% per query.


About Saama

Saama develops life science solutions that accelerate the delivery of therapies to patients. With innovative AI/ML technologies, Saama drives breakthrough intelligence into clinical and commercial operations. The Saama platform powered the clinical trial that led to the world’s first COVID-19 vaccine. Headquartered in Campbell, CA, with employees around the globe, Saama is committed to helping customers save and improve lives. Discover more at saama.com.

New Delhi, Jun 20 (PTI) The Apollo Hospitals has expanded its dedicated robotic colorectal surgery programme across six cities, including Delhi, offering minimally invasive procedures with precision and accuracy, according to a release.

It said the robotic colorectal surgery programme has been expanded to Chennai, Hyderabad, Bengaluru, Delhi, Mumbai and Vishakhapatnam.

The statement said the use of this technology and technique, particularly for colorectal cancer surgery procedures, has led to significant changes by helping surgeons to have a very precise dissection in areas such as a narrow pelvis, which ultimately leads to a drop in readmission rates, having no signs of cancer post-surgery, reduced wound infection rates and fewer post-surgery complications compared to the global market.